Pathogenicity of Saccharomyces cerevisiae in complement factor five-deficient mice
- PMID: 7822013
- PMCID: PMC173020
- DOI: 10.1128/iai.63.2.478-485.1995
Pathogenicity of Saccharomyces cerevisiae in complement factor five-deficient mice
Abstract
We have previously determined the relative virulence of isolates of Saccharomyces cerevisiae on the basis of differences in proliferation and resistance to clearance in CD-1 mice. These infections were not fatal. To further characterize S. cerevisiae pathogenesis, we studied a virulent clinical isolate, YJM128, and an avirulent nonclinical isolate, Y55, in C5-deficient mice. DBA/2N mice were infected intravenously with YJM128 or Y55, and temporal burdens of yeast cells in various organs were determined. After infection with 10(7) CFU, Y55 increased by 13-fold and YJM128 increased by 20-fold in the brain from day 0 to 3. In addition, YJM128 increased by 4-fold in the kidneys, whereas Y55 decreased by 16-fold. Both isolates declined in number in other organs. In all studies, 90% of mice infected with 10(7) CFU of YJM128 died between days 2 and 7, whereas no mice infected with equivalent numbers of Y55 died. No mice died after infection with 10(6) CFU of Y55 or YJM128. The importance of C5 was confirmed by studies using B10.D2/oSnJ (C5-) mice and their congenic C5+ counterparts. Again, the C5- mice were most susceptible to infection with S. cerevisiae, with 63% infected with YJM128 dying by day 7; no C5+ mice died. No Y55-infected mice died, and mean burdens in the brain at day 14 were sevenfold lower in C5+ mice than in C5- mice. Seven of 10 other S. cerevisiae isolates were also more virulent in DBA/2N than CD-1 mice, causing > or = 40% mortality. These data indicate that C5 is a critical factor in host resistance against S. cerevisiae infections and further confirm the pathogenic potential of some isolates of S. cerevisiae.
Similar articles
-
Correlation of the frequency of petite formation by isolates of Saccharomyces cerevisiae with virulence.Med Mycol. 2002 Apr;40(2):161-8. doi: 10.1080/mmy.40.2.161.168. Med Mycol. 2002. PMID: 12058729
-
Comparative pathogenesis of clinical and nonclinical isolates of Saccharomyces cerevisiae.J Infect Dis. 1994 Apr;169(4):859-67. doi: 10.1093/infdis/169.4.859. J Infect Dis. 1994. PMID: 8133102
-
Colony phenotype switching in clinical and non-clinical isolates of Saccharomyces cerevisiae.J Med Vet Mycol. 1996 Jul-Aug;34(4):259-64. doi: 10.1080/02681219680000441. J Med Vet Mycol. 1996. PMID: 8873885
-
Lung defenses against Pseudomonas aeruginosa in C5-deficient mice with different genetic backgrounds.Infect Immun. 1986 Jun;52(3):853-7. doi: 10.1128/iai.52.3.853-857.1986. Infect Immun. 1986. PMID: 3086235 Free PMC article.
-
Review of current methods for characterizing virulence and pathogenicity potential of industrial Saccharomyces cerevisiae strains towards humans.FEMS Yeast Res. 2015 Sep;15(6):fov057. doi: 10.1093/femsyr/fov057. Epub 2015 Jul 19. FEMS Yeast Res. 2015. PMID: 26195617 Review.
Cited by
-
Complex genetics cause and constrain fungal persistence in different parts of the mammalian body.Genetics. 2022 Nov 1;222(3):iyac138. doi: 10.1093/genetics/iyac138. Genetics. 2022. PMID: 36103708 Free PMC article.
-
Specific antibody response to oligomannosidic epitopes in Crohn's disease.Clin Diagn Lab Immunol. 1996 Mar;3(2):219-26. doi: 10.1128/cdli.3.2.219-226.1996. Clin Diagn Lab Immunol. 1996. PMID: 8991640 Free PMC article.
-
Pathogenic potential of Saccharomyces strains isolated from dietary supplements.PLoS One. 2014 May 30;9(5):e98094. doi: 10.1371/journal.pone.0098094. eCollection 2014. PLoS One. 2014. PMID: 24879417 Free PMC article.
-
Activation of the complement system by pathogenic fungi.Clin Microbiol Rev. 1996 Jan;9(1):34-46. doi: 10.1128/CMR.9.1.34. Clin Microbiol Rev. 1996. PMID: 8665475 Free PMC article. Review.
-
Complement C3 plays an essential role in the control of opportunistic fungal infections.Infect Immun. 2009 Sep;77(9):3679-85. doi: 10.1128/IAI.00233-09. Epub 2009 Jul 6. Infect Immun. 2009. PMID: 19581397 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous